Cargando…

Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation

Detalles Bibliográficos
Autores principales:	Marwah, Vikas, Choudhary, Robin, Bhati, Gaurav, Peter, Deepu K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104342/ https://www.ncbi.nlm.nih.gov/pubmed/33686995 http://dx.doi.org/10.4103/lungindia.lungindia_568_20

Ejemplares similares

COVID-19 ARDS-related pneumomediastinum and pneumothorax
por: Marwah, Vikas, et al.
Publicado: (2021)

An unusual case of spontaneous pneumomediastinum secondary to tracheal tear in a trumpeter
por: Marwah, Vikas, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Multidrug-resistant tuberculosis in COVID-19: Double trouble
por: Marwah, Vikas, et al.
Publicado: (2021)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Early experience of managing malignant pleural effusion with an indwelling pleural catheter in the Indian population
por: Shrinath, V, et al.
Publicado: (2022)

Diagnostic Yield and Safety of Bronchoscopic Lung Cryobiopsy in Evaluation of Lung Mass
por: Babu PS, Shafin, et al.
Publicado: (2021)

Pulmonary embolism in coronavirus disease 2019: the silent killer
por: Marwah, Vikas, et al.
Publicado: (2021)

Frontal encephalopathy related to hyperinflammation in COVID-19
por: Cani, Ilaria, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
por: Gasparyan, Armen Yuri, et al.
Publicado: (2022)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
por: Marwah, Vikas, et al.
Publicado: (2023)

A brewing storm: The neuropsychological sequelae of hyperinflammation due to COVID-19
por: Cothran, Thomas P., et al.
Publicado: (2020)

Clinico-etiological characteristics of organizing pneumonia: A retrospective study
por: Marwah, Vikas, et al.
Publicado: (2021)

Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021)

Rare Presentation of an Uncommon Disease
por: Marwah, Vikas, et al.
Publicado: (2022)

Massive pleural effusion masquerading as acute pulmonary thromboembolism – An unreported entity
por: Marwah, Vikas, et al.
Publicado: (2022)

Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVID‐19
por: Méndez‐Flores, Silvia, et al.
Publicado: (2022)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

Hyperinflammation, T cells, and endotoxemia
por: Inoue, Makoto, et al.
Publicado: (2015)

COVID-19 Hyperinflammation: What about Neutrophils?
por: Didangelos, Athanasios
Publicado: (2020)

Delving beneath the surface of hyperinflammation in COVID-19
por: Reddy, Kiran, et al.
Publicado: (2020)

Hyperinflammation with COVID-19: The key to patient deterioration?()()
por: Haigh, Kathryn, et al.
Publicado: (2020)

Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?
por: Taha, Sara Ibrahim, et al.
Publicado: (2022)

Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity
por: Alijotas-Reig, Jaume, et al.
Publicado: (2023)

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
por: Tanner, Tamara, et al.
Publicado: (2020)

IgGs drive COVID-19 myeloid hyperinflammation
por: Park, Matthew D.
Publicado: (2020)

Attenuating hyperinflammation in COVID-19: A change in paradigm?
por: Molnar, Zsolt, et al.
Publicado: (2020)

ACEi reduces hypertension-induced hyperinflammation in COVID-19
por: Lim, Gregory B.
Publicado: (2021)

Anti-Jo1 Syndrome: Understanding a Rare Cause of Interstitial Lung Disease
por: Hegde, Arun, et al.
Publicado: (2022)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
Publicado: (2020)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
por: -, -
Publicado: (2020)

COVID‐19: lambda interferon against viral load and hyperinflammation
por: Andreakos, Evangelos, et al.
Publicado: (2020)

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
por: Ritchie, Andrew I, et al.
Publicado: (2020)

Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19
por: Sohrabi, Yahya, et al.
Publicado: (2021)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
por: Maynard, Suzanne, et al.
Publicado: (2021)

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
por: Papadopoulou, Charalampia, et al.
Publicado: (2020)

Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
por: Geyer, Chiara E, et al.
Publicado: (2023)

SARS-CoV-2 as potential cause of cardiac inflammation and heart failure. Is it the virus, hyperinflammation, or MODS?
por: Maisch, Bernhard
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ic6vn2suncms66o1trpt5eekg1